Business
Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further
About this update from Autonomix Medical, Inc.
[{"type":"text","content":"RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces Autonomix’s FDA regulatory pathway THE WOODLANDS, TX, July 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed its previously announced transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator. The transaction, for 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license of the Apex 6 Generator intellectual property, as well as enhances the Autonomix supply chain with RF Innovations’ experienced manufacturing partner. The Apex 6 Generator is an FDA-cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system and will be a component of the sensing and ablation system submitted to gain FDA clearance for Autonomix’s technology. Autonomix plans to utilize the technology in its strategic therapeutic areas to drive value across its pipeline. “The Apex 6 Generator’s compatibility with the specifics for our radiofrequency generator ablation system de-risks incremental product development and further accelerates our journey towards FDA clearance. We are pleased to successfully execute this transaction and advance the development and commercialization of our innovative technology platform, which we believe has the potential to fill an important unmet need for patients. With this transaction now complete, we are focused on working with RF Innovations’ manufacturing partner and integrating them into our supply chain as quickly and efficiently as possible,” commented Brad Hauser, President and Chief Executive Officer of Autonomix. To facilitate equipment development, activities will begin immediately with RF Innovations’ manufacturing partner who will be incorporated into Autonomix’s manufacturing supply chain. Autonomix is initially developing its technology to address pancreatic cancer-related pain, with plans for follow-on indications p...